Related Experiment Video
Updated: Jul 18, 2026
12:45
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
beta-Blocker therapy in heart failure: scientific review
JoAnne Micale Foody1, Michael H Farrell, Harlan M Krumholz
1Yale University School of Medicine, New Haven, CT 06520-8025, USA.
JAMA
|February 20, 2002
Summary
Beta-blockers significantly reduce mortality and hospitalizations in heart failure patients. This class of drugs is now a cornerstone in managing systolic dysfunction, improving patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Heart failure management has evolved significantly, with a paradigm shift towards improved treatment strategies for systolic dysfunction.
- Beta-blockers, initially viewed with caution, are now extensively studied and proven effective in improving heart failure outcomes.
Purpose of the Study:
- To establish the scientific rationale for utilizing beta-blockers in the treatment of heart failure.
- To review evidence supporting the use of beta-blockers for improving clinical outcomes in heart failure patients.
Main Methods:
- Systematic review of large, English-language randomized controlled trials focusing on mortality benefits of beta-blockers in heart failure.
- Inclusion of basic science studies to elucidate the physiological mechanisms of beta-blockers in heart failure.
- Assessment of current clinical guidelines for beta-blocker recommendations in heart failure management.
Main Results:
- Three beta-blockers (bisoprolol, carvedilol, metoprolol) are available in the US, with carvedilol and metoprolol having FDA indications for heart failure.
- Beta-blocker therapy demonstrated a consistent 30% reduction in mortality and a 40% reduction in hospitalizations compared to placebo in patients with heart failure (Class II-III).
Conclusions:
- Beta-blockers are proven to reduce morbidity and mortality in patients with Class II-IV heart failure, based on trials involving over 10,000 participants.
- Beta-blockers, alongside other therapies like ACE inhibitors, enhance the treatment options for heart failure, necessitating effective translation of evidence into clinical practice.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...